Top

Published in:

Open Access 01-01-2018 | Guidelines and Position Statements

Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation

Authors: A. N. Schüring, T. Fehm, K. Behringer, M. Goeckenjan, P. Wimberger, M. Henes, J. Henes, M. F. Fey, M. von Wolff

Published in: Archives of Gynecology and Obstetrics | Issue 1/2018

Abstract

Purpose

Most guidelines about fertility preservation are predominantly focused on scientific evidence, but are less practically orientated. Therefore, practically oriented recommendations are needed to support the clinician in daily practice.

Methods

A selective literature search was performed based on the clinical and scientific experience of the authors, focussing on the most relevant diseases and gynaecological cancers. This article (Part I) provides information on topics that are essential for the fertility preservation indication, such as disease prognosis, disease therapy and its associated risks to fertility, recommending disease-specific fertility preservation measures. Part II specifically focusses on fertility preservation techniques.

Results

In breast cancer patients, fertility preservation such as ovarian tissue and oocyte cryopreservation is especially recommended in low-stage cancer and in women < 35 years of age. In Hodgkin’s lymphoma, the indication is mainly based on the chemotherapy regime as some therapies have very low, others very high gonadotoxicity. In borderline ovarian tumours, preservation of fertility usually is achieved through fertility sparing surgery, ovarian stimulation may also be considered. In cervical cancer, endometrial cancer, rheumatic diseases and other malignancies such as Ewing sarcoma, colorectal carcinoma, non-Hodgkin lymphoma, leukaemia etc., several other factors must be considered to enable an individual, stage-dependent decision.

Conclusion

The decision for or against fertility preservation depends on the prognosis, the risks to fertility and individual factors such as prospective family planning.

Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, Costa M, Revelli A, Salvagno F, Gennari A, Ubaldi FM, La Sala GB, De Stefano C, Wallace WH, Partridge AH, Anserini P (2016) Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 14:1. https://doi.org/10.1186/s12916-015-0545-7 PubMedPubMedCentralCrossRef

Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical Oncology (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500–2510. https://doi.org/10.1200/JCO.2013.49.2678 PubMedPubMedCentralCrossRef

von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B (2011) Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 284:427–435. https://doi.org/10.1007/s00404-011-1874-1 CrossRef

Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA (2009) Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 208:341–347PubMedPubMedCentralCrossRef

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M (2010) Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (< 35 years) with operable breast cancer. Ann Oncol 21:1974–1981PubMedCrossRef

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330. https://doi.org/10.1200/JCO.2007.14.2471 PubMedCrossRef

Han W, Kang SY, Korean Breast Cancer Society (2010) Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Clin Breast Cancer Res Treat 119:193–200CrossRef

Goldhirsch A, Gelber RD, Castiglione M (1990) The magnitude of endocrine effects of adjuvant chemotherapy for premeno- pausal breast cancer patients: the International Breast Cancer Study Group. Ann Oncol 1:183–188PubMedCrossRef

Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, Naftalis E, Naughton MJ (2010) Incidence and time course of bleeding after longterm amenorrhea after breast cancer treatment: a prospective study. Cancer 116:3102–3111PubMedCrossRef

10.

Llarena NC, Estevez SL, Tucker SL, Jeruss JS (2015) Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv202 PubMed

11.

Raphael J, Trudeau ME, Chan K (2015) Outcome of patients with pregnancy during or after breast cancer: a review of the recent literature. Curr Oncol 22:S8–S18. https://doi.org/10.3747/co.22.2338 PubMedPubMedCentralCrossRef

12.

Sanchez-Serrano M, Novella-Maestre E, Rosello-Sastre E, Camarasa N, Teruel J, Pellicer A (2009) Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod 24:2238–2243PubMedCrossRef

13.

Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, Rasmussen PE, Anderson M, Schmidt KT, Andersen CY (2011) Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril 95:2158–2161PubMedCrossRef

14.

Hoekman EJ, Smit VT, Fleming TP, Louwe LA, Fleuren GJ, Hilders CG (2015) Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach. Fertil Steril 103:469–477PubMedCrossRef

15.

Peters IT, van Zwet EW, Smit VT, Liefers GJ, Kuppen PJ, Hilders CG, Trimbos JB (2017) Prevalence and risk factors of ovarian metastases in breast cancer patients < 41 years of age in the Netherlands: a nationwide retrospective cohort study. PLoS One 12:e0168277. https://doi.org/10.1371/journal.pone.0168277 (eCollection 2017) PubMedPubMedCentralCrossRef

16.

Luyckx V, Durant JF, Camboni A, Gilliaux S, Amorim CA, Van Langendonckt A, Irenge LM, Gala JL, Donnez J, Dolmans MM (2013) Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study. J Assist Reprod Genet 30:1289–1299. https://doi.org/10.1007/s10815-013-0065-3 PubMedPubMedCentralCrossRef

17.

Bougie O, Weberpals JI (2011) Clinical considerations of BRCA1- and BRCA2- mutation carriers: a review. Int J Surg Oncol 2011:374012. https://doi.org/10.1155/2011/374012 PubMedPubMedCentral

18.

Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ (2006) Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gyneco Oncol 100:58–64CrossRef

19.

Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA (2015) Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase-III randomized trials. Lancet Oncol 16:848–858PubMedPubMedCentralCrossRef

20.

Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, Gilchrist RB, Walters KA, Abbott JA (2017) The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod 32:1033–1045. https://doi.org/10.1093/humrep/dex027 PubMedCrossRef

21.

Baynosa J, Westphal LM, Madrigrano A, Wapnir I (2009) Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg 209:603–607. https://doi.org/10.1016/j.jamcollsurg.2009.08.006 PubMedCrossRef

22.

Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, Kuchuk I, Hourvitz A, Levron J, Mozer-Mendel M, Brengauz M, Biderman H, Manela D, Catane R, Dor J, Orvieto R, Kaufman B (2014) Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril 102(488–495):e3. https://doi.org/10.1016/j.fertnstert.2014.05.017

23.

Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P (2013) Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 29:993–996. https://doi.org/10.3109/09513590.2013.819083 PubMedCrossRef

24.

Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F (2015) Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 33:2424–2429. https://doi.org/10.1200/JCO.2014.59.3723 PubMedPubMedCentralCrossRef

25.

Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101:1364–1371. https://doi.org/10.1210/jc.2015-3878 PubMedPubMedCentralCrossRef

26.

Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlputz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert A, Borchmann P (2013) Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 Trials. J Clin Oncol 31:231–239PubMedCrossRef

27.

Glimelius I, Ekberg S, Jerkeman M, Chang ET, Bjorkholm M, Andersson TM, Smedby KE, Eloranta S (2015) Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992–2009-trends in cure proportions by clinical characteristics. Am J Hematol 90:1128–1134PubMedCrossRef

28.

Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH (1997) Gonadal function following ABVD therapy for Hodgkin’s disease. Am J Clin Oncol 20:354–357PubMedCrossRef

29.

Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A, German Hodgkin’s Lymphoma Study Group (2005) Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 23:7555–7564PubMedCrossRef

30.

De Bruin ML, Huisbrink J, Hauptmann M, Kuenen MA, Ouwens GM, van’t Veer MB, Aleman BM, van Leeuwen FE (2008) Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 111:101–108PubMedCrossRef

31.

Seshadri T, Gook D, Lade S, Spencer A, Grigg A, Tiedemann K, McKendrick J, Mitchell P, Stern C, Seymour JF (2006) Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer 94:1007–1010PubMedPubMedCentralCrossRef

32.

Meirow D, Hardan I, Dor J, Fridman E, Elizur S, Ra’anani H, Slyusarevsky E, Amariglio N, Schiff E, Rechavi G, Nagler A, Ben Yehuda D (2008) Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod 23:1007–1013PubMedCrossRef

33.

Bittinger SE, Nazaretian SP, Gook DA, Parmar C, Harrup RA, Stern CJ (2011) Detection of Hodgkin lymphoma within ovarian tissue. Fertil Steril 95(803):e3–e6. https://doi.org/10.1016/j.fertnstert.2010.07.1068

34.

Seong SJ, Kim DH, Kim MK, Song T (2015) Controversies in borderline ovarian tumors. J Gynecol Oncol 26:343–349PubMedPubMedCentralCrossRef

35.

du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S, Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group (2013) Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer 49:1905–1914. https://doi.org/10.1016/j.ejca.2013.01.035 PubMedCrossRef

36.

Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P (2010) Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol 21:55–60PubMedCrossRef

37.

Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Darai E (2005) Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril 83:284–290PubMedCrossRef

38.

Mangili G, Somigliana E, Giorgione V, Martinelli F, Filippi F, Petrella MC, Candiani M, Peccatori F (2016) Fertility preservation in women with borderline ovarian tumours. Cancer Treat Rev 49:13–24. https://doi.org/10.1016/j.ctrv.2016.06.010 PubMedCrossRef

39.

Suh-Burgmann E (2006) Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 103:841–847PubMedCrossRef

40.

Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A (2014) Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol 25:1320–1327PubMedCrossRef

41.

Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB, Herzog TJ (2009) Fertility preservation in young women with epithelial ovarian cancer. Cancer 115:4118–4126PubMedCrossRef

42.

Bentivegna E, Fruscio R, Roussin S, Ceppi L, Satoh T, Kajiyama H, Uzan C, Colombo N, Gouy S, Morice P (2015) Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. Fertil Steril 104:1319–1324. https://doi.org/10.1016/j.fertnstert.2015.06.008 PubMedCrossRef

43.

Fruscio R, Ceppi L, Corso S, Galli F, Dell’Anna T, Dell’Orto F, Giuliani D, Garbi A, Chiari S, Mangioni C, Milani R, Floriani I, Colombo N, Bonazzi CM (2016) Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer 115:641–648. https://doi.org/10.1038/bjc.2016.254 PubMedPubMedCentralCrossRef

44.

Denschlag D, von Wolff M, Amant F, Kesic V, Reed N, Schneider A, Rodolakis A (2010) Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery. Gynecol Obstet Invest 70:160–165. https://doi.org/10.1159/000316264 PubMedCrossRef

45.

Rizzuto I, Behrens RF, Smith LA (2013) Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev 8:CD008215. https://doi.org/10.1002/14651858.CD008215.pub2

46.

Wallace WH, Thomson AB, Saran F, Kelsey TW (2005) Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 62:738–744PubMedCrossRef

47.

Teh WT, Stern C, Chander S, Hickey M (2014) The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int 2014:482968. https://doi.org/10.1155/2014/482968 PubMedPubMedCentralCrossRef

48.

Yamamoto R, Okamoto K, Yukiharu T, Kaneuchi M, Negishi H, Sakuragi N, Fujimoto S (2001) A study of risk factors for ovarian metastases in stage Ib–IIIb cervical carcinoma and analysis of ovarian function after a transposition. Gynecol Oncol 82:312–316PubMedCrossRef

49.

Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ (2008) Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol 32:1835–1853PubMedCrossRef

50.

Bastings L, Beerendonk CC, Westphal JR, Massuger LF, Kaal SE, van Leeuwen FE, Braat DD, Peek R (2013) Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update 19:483–506PubMedCrossRef

51.

Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, Paraskevaidis E (2014) Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ 349:g6192PubMedPubMedCentralCrossRef

52.

Wright JD, NathavithArana R, Lewin SN, Sun X, Deutsch I, Burke WM, Herzog TJ (2010) Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol 115:585–590. https://doi.org/10.1097/AOG.0b013e3181d06b68 PubMedCrossRef

53.

Spoozak L, Lewin SN, Burke WM, Deutsch I, Sun X, Herzog TJ, Wright JD (2012) Microinvasive adenocarcinoma of the cervix. Am J Obstet Gynecol 206:80.e1–80.e6. https://doi.org/10.1016/j.ajog.2011.07.029 CrossRef

54.

D’argent D, Martin X, Sacchetoni A, Mathevet P (2000) Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 88:1877–1882CrossRef

55.

Vercellino GF, Piek JM, Schneider A, Kohler C, Mangler M, Speiser D, Chiantera V (2012) Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer. Gynecol Oncol 126:325–329PubMedCrossRef

56.

Slama J, Cerny A, Dusek L, Fischerova D, Zikan M, Kocian R, Germanova A, Cibula D (2016) Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5 years of experience. Gynecol Oncol 142:401–404. https://doi.org/10.1016/j.ygyno.2016.07.008 PubMedCrossRef

57.

Zapardiel I, Cruz M, Diestro MD, Requena A, Garcia-Velasco JA (2016) Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers. Hum Reprod Update. https://doi.org/10.1093/humupd/dmv066 PubMed

58.

Lyu J, Sun T, Tan X (2014) Ovarian preservation in young patients with stage I cervical adenocarcinoma: a surveillance, epidemiology, and end results study. Int J Gynecol Cancer 24:1513–1520PubMedCrossRef

59.

Robova H, Halaska MJ, Pluta M, Skapa P, Matecha J, Lisy J, Rob L (2014) Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. Gynecol Oncol 135:213–216PubMedCrossRef

60.

Bentivegna E, Maulard A, Pautier P, Chargari C, Gouy S, Morice P (2016) Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertil Steril 106(1195–1211):e5. https://doi.org/10.1016/j.fertnstert.2016.06.032

61.

Willows K, Lennox G, Covens A (2016) Fertility-sparing management in cervical cancer: balancing oncologic outcomes with reproductive success. Gynecol Oncol Res Pract 3:9 (eCollection 2016) PubMedPubMedCentralCrossRef

62.

Okugawa K, Kobayashi H, Sonoda K, Kaneki E, Kawano Y, Hidaka N, Egashira K, Fujita Y, Yahata H, Kato K (2017) Oncologic and obstetric outcomes and complications during pregnancy after fertility-sparing abdominal trachelectomy for cervical cancer: a retrospective review. Int J Clin Oncol 22:340–346. https://doi.org/10.1007/s10147-016-1059-9 PubMedCrossRef

63.

Feng Y, Cao T, Wang Y, Huang H, Xie Y, Liu J (2016) Neoadjuvant chemotherapy followed by conization to spare fertility in cases of locally advanced cervical cancer: a case report and review of the literature. Mol Clin Oncol 5:411–416PubMedPubMedCentralCrossRef

64.

Mossa B, Schimberni M, Di Benedetto L, Mossa S (2015) Ovarian transposition in young women and fertility sparing. Eur Rev Med Pharmacol Sci 19:3418–3425PubMed

65.

Kinjyo Y, Kudaka W, Ooyama T, Inamine M, Nagai Y, Aoki Y (2015) Ovarian preservation in young women with endometrial cancer of endometrioid histology. Acta Obstet Gynecol Scand 94:430–434. https://doi.org/10.1111/aogs.12588 PubMedCrossRef

66.

Dogan A, Schultheis B, Rezniczek GA, Hilal Z, Cetin C, Häusler G, Tempfer CB (2017) Synchronous endometrial and ovarian cancer in young women: case report and review of the literature. Anticancer Res 37:969–978PubMedCrossRef

67.

Shan BE, Ren YL, Sun JM, Tu XY, Jiang ZX, Ju XZ, Zang RY, Wang HY (2013) A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet 288:1115–1123PubMedCrossRef

68.

Kim MK, Seong SJ, Kim YS, Song T, Kim ML, Yoon BS, Jun HS, Lee YH (2013) Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. Am J Obstet Gynecol 209:358.e1–358.e4CrossRef

69.

Kalogera E, Dowdy SC, Bakkum-Gamez JN (2014) Preserving fertility in young patients with endometrial cancer: current perspectives. Int J Womens Health 6:691–701PubMedPubMedCentral

70.

Pronin SM, Novikova OV, Andreeva JY, Novikova EG (2015) Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer 25:1010–1014PubMedCrossRef

71.

Poilblanc M, Samouelian V, Querleu D (2012) Ovarian preservation during treatment of early stage endometrial cancer. Bull Cancer 99:61–68PubMed

72.

Zivanovic O, Carter J, Kauff ND, Barakat RR (2009) A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 115:504–509PubMedCrossRef

73.

Lee TS, Lee JY, Kim JW, Oh S, Seong SJ, Lee JM, Kim TJ, Cho CH, Kim SM, Park CY (2013) Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study. Gynecol Oncol 131:289–293PubMedCrossRef

74.

Wright JD, Jorge S, Tergas AI, Hou JY, Burke WM, Huang Y, Hu JC, Ananth CV, Neugut AI, Hershman DL (2016) Utilization and outcomes of ovarian conservation in premenopausal women with endometrial cancer. Obstet Gynecol 127:101–108. https://doi.org/10.1097/AOG.0000000000001181 PubMedPubMedCentralCrossRef

75.

Park JY, Nam JH (2015) Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist 20:270–278PubMedPubMedCentralCrossRef

76.

Inoue O, Hamatani T, Susumu N, Yamagami W, Ogawa S, Takemoto T, Hirasawa A, Banno K, Kuji N, Tanaka M, Aoki D (2016) Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reprod Biol Endocrinol 14:2. https://doi.org/10.1186/s12958-015-0136-7 PubMedPubMedCentralCrossRef

77.

Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM (2002) Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 29:2129–2135PubMed

78.

Park MC, Park YB, Jung SY, Sbai A, Costedoat N, Wechsler B, Piette JC (2004) Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 13:569–574PubMedCrossRef

79.

Henes M, Froeschlin J, Taran FA, Brucker S, Rall KK, Xenitidis T, Igney-Oertel A, Lawrenz B, Henes J (2015) Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behcet’s disease and spondyloarthritis on anti-Mullerian hormone levels. Rheumatology (Oxford) 54:1709–1712CrossRef

80.

Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, Kotter I (2011) Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus 20:1193–1197PubMedCrossRef

81.

Mont’Alverne AR, Pereira RM, Yamakami L, Viana VS, Baracat EC, Bonfa E, Silva CA (2014) Reduced ovarian reserve in patients with takayasu arteriitis. J Rheumatol 41:2055–2059PubMedCrossRef

82.

Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R, Forger F, Moraes-Fontes MF, Khamashta M, King J, Lojacono A, Marchiori F, Meroni PL, Mosca M, Motta M, Ostensen M, Pamfil C, Raio L, Schneider M, Svenungsson E, Tektonidou M, Yavuz S, Boumpas D, Tincani A (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76:476–485. https://doi.org/10.1136/annrheumdis-2016-209770 PubMedPubMedCentralCrossRef

83.

Mok CC, Wong RW, Lau CS (1999) Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 42:1274–1280PubMedCrossRef

84.

von Wolff M, Stute P (2017) Judging the fertility protective effect of GnRH agonists in chemotherapy—it is a matter of perspective. Front Endocrinol (Lausanne) 10(8):69. https://doi.org/10.3389/fendo.2017.00069

85.

Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697PubMedCrossRef

86.

Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ (2005) Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52:2761–2767PubMedCrossRef

87.

Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M (2009) Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 9:401–405CrossRef

88.

Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, Christman GM, Somers EC (2012) Adjunctive GnRH—a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol 28:624–627PubMedPubMedCentralCrossRef

89.

Guballa N, Sammaritano L, Schwartzman S, Buyon J, Lockshin MD (2000) Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 43:550–556PubMedCrossRef

90.

Reynaud Q, Lega JC, Mismetti P, Chapelle C, Wahl D, Cathebras P, Laporte S (2014) Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 13:595–608PubMedCrossRef

91.

Raciborska A, Bilska K, Filipp E, Drabko K, Rogowska E, Chaber R, Pogorzała M, Połczyńska K, Adrianowska N, Rodriguez-Galindo C, Maciejewski T (2015) Ovarian function in female survivors after multimodal Ewing sarcoma therapy. Pediatr Blood Cancer 62:341–345. https://doi.org/10.1002/pbc.25304 PubMedCrossRef

92.

Greve T, Wielenga VT, Grauslund M, Sorensen N, Christiansen DB, Rosendahl M, Yding Andersen C (2013) Ovarian tissue cryopreserved for fertility preservation from patients with Ewing or other sarcomas appear to have no tumour cell contamination. Eur J Cancer 49:1932–1938PubMedCrossRef

93.

Abir R, Feinmesser M, Yaniv I, Fisch B, Cohen IJ, Ben-Haroush A, Meirow D, Felz C, Avigad S (2010) Occasional involvement of the ovary in Ewing sarcoma. Hum Reprod 25:1708–1712PubMedCrossRef

94.

Sorensen SD, Greve T, Wielenga VT, Wallace WH, Andersen CY (2014) Safety considerations for transplanting cryopreserved ovarian tissue to restore fertility in female patients who have recovered from Ewing’s sarcoma. Future Oncol 10:277–283PubMedCrossRef

95.

Dolmans MM, Iwahara Y, Donnez J, Soares M, Vaerman JL, Amorim CA, Poirel H (2016) Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients. Hum Reprod 31:2292–2302. https://doi.org/10.1093/humrep/dew193 PubMedCrossRef

96.

Irtan S, Orbach D, Helfre S, Sarnacki S (2013) Ovarian transposition in prepubescent and adolescent girls with cancer. Lancet Oncol 14:601–608CrossRef

97.

Longhi A, Pignotti E, Versari M, Asta S, Bacci G (2003) Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Oncol Rep 10:151–155PubMed

98.

Strong M, Peche W, Scaife C (2007) Incidence of fertility counseling of women of child-bearing age before treatment for colorectal cancer. Am J Surg 194:765–767 (discussion 767–768) PubMedCrossRef

99.

O’Neill MT, Ni Dhonnchu T, Brannigan AE (2011) Topic update: effects of colorectal cancer treatments on female fertility and potential methods for fertility preservation. Dis Colon Rectum 54:363–369PubMedCrossRef

100.

Wan J, Gai Y, Li G, Tao Z, Zhang Z (2015) Incidence of chemotherapy- and chemoradiotherapy-induced amenorrhea in premenopausal women with stage II/III colorectal cancer. Clin Colorectal Cancer 14:31–34. https://doi.org/10.1016/j.clcc.2014.09.012 PubMedCrossRef

101.

Elis A, Tevet A, Yerushalmi R, Blickstein D, Bairy O, Dann EJ, Blumenfeld Z, Abraham A, Manor Y, Shpilberg O, Lishner M (2006) Fertility status among women treated for aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 47:623–627PubMedCrossRef

102.

Carter A, Robison LL, Francisco L, Smith D, Grant M, Baker KS, Gurney JG, McGlave PB, Weisdorf DJ, Forman SJ, Bhatia S (2006) Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transpl 37:1023–1029CrossRef

103.

Briseno-Hernandez AA, Quezada-Lopez DR, Castaneda-Chavez A, Dassaejv Macias-Amezcua M, Pintor-Belmontes JC (2014) Bilateral ovarian Burkitt’s lymphoma. A case presentation. Cir Cir 82:212–218PubMed

104.

Jadoul P, Kim SS, ISFP Practice Committee (2012) Fertility considerations in young women with hematological malignancies. J Assist Reprod Genet 29:479–487. https://doi.org/10.1007/s10815-012-9792-0 PubMedPubMedCentralCrossRef

105.

Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Douer D, Frankfurt O, Greer JP, Johnson RA, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Rao AV, Shah B, Uy GL, Wang ES, Zelenetz AD, Gregory K, Smith C (2015) Acute lymphoblastic leukemia, version 2.2015. J Natl Compr Canc Netw 10:1240–1279CrossRef

106.

Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J (2010) Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 116:2908–2914PubMedCrossRef

107.

Practice Committee ISFP, Kim SS, Donnez J, Barri P, Pellicer A, Patrizio P, Rosenwaks Z, Nagy P, Falcone T, Andersen C, Hovatta O, Wallace H, Meirow D, Gook D, Kim SH, Tzeng CR, Suzuki S, Ishizuka B, Dolmans MM (2012) Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet 29:465–468. https://doi.org/10.1007/s10815-012-9786-y CrossRef

108.

Salooja N, Szydlo RM, Socie G, Rio B, Chatterjee R, Ljungman P, Van Lint MT, Powles R, Jackson G, Hinterberger-Fischer M, Kolb HJ, Apperley JF, Late Effects Working Party of the European Group for Blood and Marrow Transplantation (2001) Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 358:271–276PubMedCrossRef

109.

Hurmuz P, Sebag-Montefiore D, Byrne P, Cooper R (2012) Successful spontaneous pregnancy after pelvic chemoradiotherapy for anal cancer. Clin Oncol (R Coll Radiol) 24:455–457CrossRef

110.

De Menezes E, Tuck SM (2007) Pelvic radiotherapy damage to the endometrium causing morbid adherence of placenta. A new risk factor? J Obstet Gynaecol 27:526–527PubMedCrossRef

111.

Bath LE, Tydeman G, Critchley HO, Anderson RA, Baird DT, Wallace WH (2004) Spontaneous conception in a young woman who had ovarian cortical tissue cryopreserved before chemotherapy and radiotherapy for a Ewing’s sarcoma of the pelvis: case report. Hum Reprod 19:2569–2572PubMedCrossRef

112.

Wallace WH, Thomson AB, Kelsey TW (2003) The radiosensitivity of the human oocyte. Hum Reprod 18:117–121PubMedCrossRef

113.

Muñoz M, Santaballa A, Seguí MA, Beato C, de la Cruz S, Espinosa J, Fonseca PJ, Perez J, Quintanar T, Blasco A (2016) SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients. Clin Transl Oncol 18:1229–1236PubMedPubMedCentralCrossRef

114.

Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K, American Society of Clinical Oncology (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917–2931PubMedCrossRef

Title: Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation
Authors: A. N. Schüring
T. Fehm
K. Behringer
M. Goeckenjan
P. Wimberger
M. Henes
J. Henes
M. F. Fey
M. von Wolff
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 1/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-017-4594-3

At a glance: The STEP trials

Springer Medicine

Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Maternal sepsis in the era of genomic medicine

Knockdown of E-cadherin expression of endometrial epithelial cells may activate Wnt/β-catenin pathway in vitro

Fertility after uterine artery embolization of fibroids: a systematic review

Prediction of vaginal birth after one ceasarean delivery for non-progressive labor

Maternal pre-pregnancy obesity and the risk of macrosomia: a meta-analysis

Vulvar involvement in pediatric Crohn’s disease: a systematic review